August 17, 2021

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ms. Margaret Schwartz

Re: Aptevo Therapeutics Inc.

Registration Statement on Form S-3
File No. 333-258758

Dear Ms. Schwartz:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-258758) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:05 p.m., Eastern Time, on August 19, 2021 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Goodwin Procter LLP, by calling Sean M. Donahue at (202) 538-3557.

Very truly yours,

Aptevo Therapeutics Inc.

By: /s/ Marvin L. White

Marvin L. White

President and Chief Executive Officer

CC: SoYoung Kwon, Aptevo Therapeutics Inc.
Daphne Taylor, Aptevo Therapeutics Inc.  
Sean M. Donahue, Goodwin Procter LLP

 

2401 4^th Ave. Suite 1050, Seattle, WA 98121  |  t 206.838.0500  | f  206.838.0503  |  aptevotherapeutics.com  |  1